Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas.
Alterations in the p53 gene have been described in a variety of human malignant neoplasms. We have examined 29 stage B prostate carcinomas for alterations in the p53 gene and for amplification of the MDM-2 gene. No evidence of mutations in the conserved exons 5 to 8 was found by polymerase chain reaction single-stranded conformation polymorphism analysis and no accumulation of p53 protein was found by immunohistochemistry. However, loss of heterozygosity at the p53 locus was observed in 11% of information cases. Amplification of the MDM-2 gene was not observed by Southern blot hybridization. In contrast, stage C and D prostate carcinomas showed accumulation of p53 protein in 33 to 66% of cases. We conclude that alterations in p53 function are infrequent in clinically localized prostate cancers but are more common in advanced cancers.
Ittmann
M
M
Department of Pathology, New York Department of Veterans Affairs Medical Center 10010.
Wieczorek
R
R
Heller
P
P
Dave
A
A
Provet
J
J
Krolewski
J
J
D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology; D002874:Chromosome Mapping; D004273:DNA, Neoplasm / Q000235:genetics; D004277:DNA, Single-Stranded / Q000235:genetics; D005091:Exons; D005784:Gene Amplification; D005796:Genes; D006579:Heterozygote; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009363:Neoplasm Proteins / Q000235:genetics*; D009367:Neoplasm Staging; D009687:Nuclear Proteins; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D011518:Proto-Oncogene Proteins; D051736:Proto-Oncogene Proteins c-mdm2; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D004273:DNA, Neoplasm; D004277:DNA, Single-Stranded; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2